Composition:

Each film-coated LuciLorla tablet contains: Lorlatinib 25mg
Each film-coated LuciLorla tablet contains: Lorlatinib 100mg

INDICATION:  

LuciLorla is for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC)

DOSAGE AND USE:

Recommended dosage: 100 mg orally once daily.

Severe Renal Impairment: 75 mg orally once daily.

Tablets should be swallowed whole & not chewed or crushed.

STORAGE: 

Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).

Keep medicine out of the reach of Children.

MANUFACTURED AND MARKETED BY: 

LUCIUS PHARMACEUTICALS(LAO) CO., LTD

No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

WARNING AND PRECAUTION:

To be sold by retail on prescription of registered physicians only, and as directed by the physician.